Movement Disorders: Clinical Trials

6,073 trials for Movement Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3197 completed, 925 unknown, 857 recruiting, 355 terminated. 2493 Not applicable, 917 Phase 2, 604 Phase 1, 414 Phase 3, 224 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable2493Completed 1176, Unknown 475, Recruiting 408, Not yet recruiting 134, Terminated 110, Active not recruiting 86, Enrolling by invitation 49, Withdrawn 49, Suspended 6
Phase 2917Completed 541, Unknown 87, Terminated 86, Recruiting 81, Active not recruiting 45, Withdrawn 37, Not yet recruiting 29, Enrolling by invitation 8, Suspended 3
Phase 1604Completed 379, Recruiting 64, Unknown 47, Terminated 37, Active not recruiting 26, Not yet recruiting 26, Withdrawn 21, Enrolling by invitation 3, Suspended 1
Phase 3414Completed 285, Terminated 51, Recruiting 28, Unknown 23, Withdrawn 11, Active not recruiting 10, Not yet recruiting 4, Enrolling by invitation 2
Phase 4224Completed 138, Unknown 34, Terminated 19, Recruiting 14, Not yet recruiting 6, Withdrawn 6, Enrolling by invitation 5, Active not recruiting 1, Suspended 1
Early Phase 189Completed 41, Recruiting 19, Unknown 10, Terminated 7, Not yet recruiting 6, Withdrawn 4, Active not recruiting 2

Follow Movement Disorders: new trials by email Literature Review of Movement Disorders trials Research Report on Movement Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Terazosin And Metabolic Energetics in Parkinson's Disease
Terazosin 5 MG, Placebo - Parkinson's Disease (PD)
Phase 2SuspendedErgun Y. Uc1202028-07-012026-10-09
Double-Blind Clinical Trial of Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease
active subthalamic nucleus deep brain stimulation plus optimal drug therapy, inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy - Parkinson Disease
Not applicableNot yet recruitingMallory Hacker402028-01-012026-02-20
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.
Gemfibrozil, Placebo - Parkinson Disease
Phase 2WithdrawnForest Hills Lab2027-11-012026-08-19
Terazosin for Dementia With Lewy Bodies
Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies
Phase 1 / Phase 2Not yet recruitingQiang Zhang402027-10-012026-03-12
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease
MT101-5 - Parkinson's Disease
Phase 2Not yet recruitingMthera Pharma Co., Ltd.1202027-09-012026-10-16
Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)
rTMS - Parkinson Disease
Not applicableNot yet recruitingUniversity of Michigan202027-09-012026-10-20
Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics
Levodopa (L-dopa) - Parkinson's Disease
Phase 4Not yet recruitingBeth Israel Deaconess Medical Center402027-07-012026-08-28
Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease
Fecal Microbiota Transplant - Parkinson Disease
Phase 1Not yet recruitingProgenaBiome102027-07-012026-10-09
Engage-PD: a Physical Activity Coaching Program Via Telehealth for People With Parkinson's Disease. A Single-cohort Study in Spain.
Physical Activity Coaching - PARKINSON DISEASE (Disorder)
Not applicableNot yet recruitingHospital Clinic of Barcelona302027-06-012026-10-05
Sustained Release Oral Formulation For Treatment Of Parkinsons Disease
Formulation A, Formulation B, Formulation C - Healthy Volunteers
Phase 1 / Phase 2Not yet recruitingUniversity of Minnesota322027-04-012026-10-01
Expiratory Muscle Training in Parkinson's Disease With Forward Trunk Flexion
Expiratory muscle strength training - Parkinson's Disease
Not applicableNot yet recruitingGeneral University Hospital, Prague282027-02-012026-11-12
Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease
Huntington Disease
Not yet recruitingBioSensics752027-01-312026-10-13
A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)
AB-1005 - Parkinson Disease
Phase 2Not yet recruitingBayer82027-01-252026-07-29
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Not yet recruitingBioSensics602027-01-152026-10-13
Magnetic-Resonance Guided Focused Ultrasound Pallidothalamic Tractotomy for Parkinson's Disease
MR-guided Focused Ultrasound Pallidothalamic Tractotomy, MR-guided Focused Ultrasound VIM Thalamotomy, Combined MR-guided Focused Ultrasound PTT and VIM Treatment - Parkinson Disease (PD)
Not applicableNot yet recruitingResearch Center of Neurology, Russia1682027-01-152026-11-12
Strength and Dual-Task on Sarcopenia in People With Parkinson's Disease
Nutricional Education and General Exercise Guidelines, Progressive Resistance Training With Cognitive Dual-Task Training, Progressive Resistance Training With Cognitive Dual-Task and Inestability Training - PARKINSON DISEASE (Disorder), Parkinsonism or Parkinson's Disease Nos
Not applicableRecruitingUniversity of Valencia602027-01-112026-10-30
Exploring the Efficacy of the Effortful Swallow Maneuver for Improving Swallowing in People With PD
Effortful swallow - Dysphagia, Parkinson Disease (PD)
Not applicableNot yet recruitingUniversity of Alberta742027-01-012026-08-19
A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)
ONO-2808, Placebo - Multiple System Atrophy, Parkinson Variant
Phase 3Not yet recruitingOno Pharmaceutical Co., Ltd.4862027-01-012026-09-17
Probing Gut-Brain Communication in Parkinson's Disease
taVNS, Sham taVNS - Parkinson Disease (PD)
Not applicableNot yet recruitingSpaulding Rehabilitation Hospital452027-01-012026-10-08
Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease
Talineuren, Placebo - Parkinson Disease
Phase 2Not yet recruitingInnoMedica Schweiz AG402027-01-012026-10-30

Showing 20 of 6073. Sign in to see all of them.

Narrower conditions

Parkinson Disease (4498)  ·  Huntington Disease (292)  ·  Essential Tremor (267)  ·  Lewy Body Disease (237)  ·  Alzheimer Disease (234)  ·  Tourette Syndrome (234)  ·  Parkinsonian Disorders (214)  ·  Multiple System Atrophy (204)  ·  Dyskinesias (174)  ·  Supranuclear Palsy, Progressive (171)  ·  Cognitive Dysfunction (170)  ·  Motor Activity (167)  ·  Neurodegenerative Diseases (159)  ·  Dementia (155)

Broader conditions

Central Nervous System Diseases (6008)  ·  Nervous System Diseases (5970)  ·  Brain Diseases (5493)  ·  Basal Ganglia Diseases (5464)  ·  Neurodegenerative Diseases (5316)  ·  Synucleinopathies (4737)  ·  Parkinsonian Disorders (4502)  ·  Pathological Conditions, Signs and Symptoms (1387)  ·  Mental Disorders (1294)  ·  Signs and Symptoms (1205)  ·  Neurologic Manifestations (1063)  ·  Neurocognitive Disorders (789)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (725)  ·  Genetic Diseases, Inborn (706)

Interventions

Deep Brain Stimulation (110)  ·  Levodopa (93)  ·  Exercise (85)  ·  carbidopa, levodopa drug combination (80)  ·  Transcranial Magnetic Stimulation (71)  ·  Transcranial Direct Current Stimulation (61)  ·  Pramipexole (47)  ·  rasagiline (47)  ·  opicapone (43)  ·  rotigotine (43)  ·  Physical Therapy Modalities (39)  ·  Carbidopa (37)  ·  Blood Specimen Collection (30)  ·  Control Groups (29)  ·  Apomorphine (27)

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS) (139)  ·  University of Florida (59)  ·  Bial - Portela C S.A. (56)  ·  Assistance Publique - Hôpitaux de Paris (48)  ·  Boehringer Ingelheim (44)  ·  University of Minnesota (44)  ·  Oregon Health and Science University (43)  ·  VA Office of Research and Development (43)  ·  University Hospital, Toulouse (42)  ·  Institut National de la Santé Et de la Recherche Médicale, France (41)  ·  Washington University School of Medicine (40)  ·  Radboud University Medical Center (36)  ·  University of Colorado, Denver (35)  ·  AbbVie (34)  ·  Vanderbilt University Medical Center (34)

Countries

United States (2385)  ·  France (627)  ·  Italy (441)  ·  Germany (390)  ·  Canada (386)  ·  China (376)  ·  United Kingdom (373)  ·  Spain (318)  ·  Turkey (Türkiye) (183)  ·  Netherlands (159)  ·  Israel (148)  ·  Taiwan (147)  ·  Poland (124)  ·  Brazil (119)  ·  Australia (112)

Top investigators

Mark Hallett, M.D. (20)  ·  Giuseppe Frazzitta, MD (18)  ·  Italo Biaggioni, MD (15)  ·  Danna Jennings, MD (12)

Results publications

PMID 36602886, PMID 38588457, PMID 40680102, PMID 31356217, PMID 36463457, PMID 38489195, PMID 38557959, PMID 25623333, PMID 29480210, PMID 30741694, PMID 31127735, PMID 31381524, PMID 31617235, PMID 32250312, PMID 10816186, PMID 19025984, PMID 19126811, PMID 25962554, PMID 27538531, PMID 28494751, PMID 30776019, PMID 34816053, PMID 35995551, PMID 36811812, PMID 38825840, PMID 41626017, PMID 11253156, PMID 12112073, PMID 12360555, PMID 12498954, PMID 1454205, PMID 15097290, PMID 16267188, PMID 16401616, PMID 16436781, PMID 17941858, PMID 19058133, PMID 20457959, PMID 20483969, PMID 20519680, PMID 20574039, PMID 20582993, PMID 20841416, PMID 20937936, PMID 20946640, PMID 21484867, PMID 21542016, PMID 21594724, PMID 22209649, PMID 22750016

NIH funding

2016 (20), 2023 (20), 2019 (19), 2025 (18), 2014 (17), 2018 (16), 2017 (15), 2009 (13), 2008 (12), 2015 (10), 2004 (7), 2005 (4), R01AG085029 (3), R01HL144568 (3), U01NS043128 (3)